CXCR4 drugs for Multiple Myeloma
3 tracked CXCR4 drugs in the Multiple Myeloma race. The class explanation lives on the CXCR4 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
2 approved / phase 41 Phase 2
Head-to-head evidence: Burixafor (TG-0054) vs Motixafortide · Burixafor (TG-0054) vs Plerixafor · Motixafortide vs Plerixafor